Vanguard Global Advisers
XFOR icon

Vanguard Global Advisers’s X4 Pharmaceuticals XFOR Stock Holding History

Vanguard Global Advisers’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$154K Hold
32,977
– – ﹤0.01% 2606
2026
Q1 		$136K Buy
+32,977
New +$124K ﹤0.01% 2598

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $140M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Global Advisers's XFOR Position: Q2 2026 in Review

Vanguard Global Advisers held its X4 Pharmaceuticals (XFOR) position steady in Q2 2026 at 32,977 shares worth $154K. The position accounts for ﹤0.01% of the portfolio, ranked #2606.

Vanguard Global Advisers first reported a position in XFOR in Q1 2026 and has held it in 2 quarters since. 88 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

  • Vanguard Global Advisers held 32,977 shares of X4 Pharmaceuticals worth $154K as of Q2 2026.
  • Vanguard Global Advisers left its X4 Pharmaceuticals share count unchanged in Q2 2026.
  • X4 Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2606 holding.
  • Vanguard Global Advisers first reported a position in X4 Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 88 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.